William Eward, MD, DVM
With the approval of pexidartinib (Turalio) in August 2019
as the sole advancement in tenosynovial giant cell tumor (TGCT) treatment in several years, William Eward, MD, DVM, believes physicians need to conduct research in this space with a more open-minded approach.
“Historically, we haven't had great treatments for TGCT. You can cut [the tumor] out, but it comes back at least 30% of the time. You can treat it with radiation therapy but being exposed to radiation causes cancer. You hate to give someone cancer by treating them for something that's not cancer,” said Eward, an associate professor and orthopedic surgical oncologist at Duke Cancer Institute.
In an interview with OncLive®, Eward discussed the use of pexidartinib and other options to treat patients with TGCT, as well as future recommendations for the field, such as using comparative oncology when researching drugs.
... to read the full story